ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$24.97
−1.46%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$25.43
From 52W high−35.14%
Volume1.39M
Market cap$508.40M
P/E (TTM)45.4x
P/S (TTM)6.8x
Div yield—
Key dataSep 18, 2026
Open
$25.43
From 52W high
−35.14%
Volume
1.39M
Market cap
$508.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2799.9x
P/E (TTM)
45.4x
RSI (14)
30.0
MomentumView details →
1D Return
−1.46%
YTD Return
−26.87%
SummaryUpdated Jun 1, 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotechnology company founded in 2005 and headquartered in South San Francisco, California. Originally incorporated as Ventrus Biosciences, the company changed its name to Assembly Biosciences in June 2014. The company went public in December 2010 and focuses exclusively on developing therapeutic treatments for hepatitis B virus (HBV) infection, a serious liver disease that affects hundreds of millions of people worldwide.
Similar companies
Latest newsMore news →
Assembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.12d agoAssembly Biosciences reported a Q2 2026 loss of $0.20 per share, beating the Zacks Consensus Estimate of a $0.70 loss and improving from a $1.33 loss a year earlier.38d ago